Akeso Lung Cancer Drug Approved in China After Outperforming Keytruda in Head-to-Head Trial

Akeso Inc. received approval in China this week for its lung cancer drug, following a head-to-head clinical trial where it outperformed Merck’s Keytruda. The drug will now be available for use within the Chinese market. The approval follows the completion of a direct comparative study. In this study, Akeso’s drug demonstrated superior results when compared to Keytruda. As a result, Chinese regulators granted approval for its use in treating lung cancer patients.

Newsflash | Powered by GeneOnline AI
Date: April 25, 2025

Related posts:

Experts Recommend Statin Therapy for ASCVD Primary Prevention When 10-Year Risk Exceeds 7.5% Study Links Increased Screen Time to Loneliness, Depression, and Body Image Issues in 18-25 Year Olds. Breast Cancer Mortality Declines Across Subtypes, Data Analysis Shows. Experts: Patient Journey Understanding, Complex Value Chain Management, and Targeted Patient Matching Drive Successful Adoption of New Medical Treatments

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後